Form 4: Vivos Therapeutics Director Mark F. Lindsay Acquires 4,000 Stock Options

Director Mark F. Lindsay of Vivos Therapeutics, Inc. acquired 4,000 stock options on June 20, 2024, as reported in a Form 4 filing with the SEC.

Summary

• Mark F. Lindsay, a director of Vivos Therapeutics, Inc., reported the acquisition of 4,000 stock options on June 20, 2024.
• The exercise price of these options is $2.38.
• Half of the options vested immediately, with the remaining portions vesting on September 30, 2024, and December 31, 2024.
• Following the transaction, Lindsay directly owns 7,067 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither particularly positive nor negative on its own. The director's increased stake could be seen as a mild positive.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a common practice of granting stock options to company directors as part of their compensation package. It's typical for companies to use stock options to align the interests of directors with those of shareholders.

Key Dates